Biom’Up, a Saint-Priest, France-based specialist in collagen-based absorbable medical devices for biosurgery, secured €31.3m in Series C financing.
Backers included Gimv, Bpifrance Large Venture and Lundbeckfond Ventures, existing shareholders InnoBio, Sham Innovation Santé, ACG Management, Sofimac, Mérieux Développement, OTC AM, Euroainvest and l’Améliane and the company’s management team. In conjunction with the funding, Dr. Karl Naegler (Gimv), Dr. Laurent Higueret (Bpifrance Large Venture) and Mr. Casper Breum (Lundbeckfond Ventures) joined Biom’Up’s board.
The company intends to use the funds to finance further development of HEMOBLAST TM, particularly in the context of its clinical study conducted in Europe
and North America.
Led by Étienne Binant, CEO, Biom’Up is developing a new generation hemostatic product, HEMOBLAST TM, and markets its proprietary products COVATM, COVAMESHTM and MATRITMBONE.
The company achieved a turnover of more than €3m in 2014 and expects more than 30% growth in sales of its existing product portfolio for 2015.